Cipla (CIPLA) — Financial Results

Cipla reported Q1 FY26 revenue of ₹6,957 crores, up 69.9% YoY, with PAT margin at 18.7% and EBITDA margin at 25.6%. U.S. revenue reached $226 million, driven by new launches and a $1 billion FY27 sales target. R&D investment rose to ₹432 crores (6.2% of revenue), supporting biosimilars and GLP-1 entries. Net cash stood at ₹10,379 crores, while total debt was ₹459 crores. Chronic segment contributes 61.5% of sales, with 23 brands in the top 300. India revenue crossed ₹3,000 crores, representing 44% of global sales. Respiratory growth is expected to align with the 4-5% industry rate, supported by triple-combination launches and margin resilience despite Revlimid's phased exit.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this financial results affect Cipla Limited's outlook?" "What did Cipla Limited announce on 28 July 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 28 July 2025

SHRIRAMFIN Shriram Finance Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Announcement TORNTPHARM Torrent Pharmaceuticals Limited Financial Results RECLTD REC Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.